PT  - JOURNAL ARTICLE
AU  - Gauthier, Lynn R.
AU  - Robichaud, Lye-Ann
AU  - Bouffard, Maud
AU  - Therrien, Frédérique
AU  - Béland, Sarah
AU  - Bouvrette, Marianne
AU  - Gewandter, Jennifer
AU  - Gagliese, Lucia
AU  - Dworkin, Robert H
AU  - Lemieux, Julie
AU  - Savard, Josée
AU  - Jackson, Philip L.
AU  - Aubin, Michèle
AU  - Lauzier, Sophie
AU  - Gagnon, Bruno
AU  - Dionne, Anne
AU  - Shobbrook, Cindy
AU  - Gagnon, Pierre
TI  - Factors associated with chemotherapy-induced peripheral neuropathy-related reduced taxane dose or premature discontinuation in women with early-stage breast cancer
AID  - 10.1101/2021.09.13.21263539
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.13.21263539
4099  - http://medrxiv.org/content/early/2021/09/16/2021.09.13.21263539.short
4100  - http://medrxiv.org/content/early/2021/09/16/2021.09.13.21263539.full
AB  - Purpose In the absence of treatments for chemotherapy-induced peripheral neuropathy (CIPN), dose reductions (DR) and premature discontinuation (PD) are primary management strategies. However, decision-making guidance is insufficient and knowledge of factors associated with DR/PD is limited. We examined biopsychosocial factors associated with CIPN-related DR/PD in women undergoing taxane-based chemotherapy for early-stage breast cancer.Patients and methods As part of a longitudinal study of CIPN measurement, women completed assessments before the first taxane infusion and at the final infusion or within the originally expected timeframe for the final infusion. Participants completed self-report measures of CIPN, pain, and physical and psychosocial wellbeing, and underwent physical testing of lower limb disability and Quantitative Sensory Testing for sensation and pain threshold to thermal, vibration, and touch stimuli in the feet and hands. Sociodemographic and clinical data were collected. Logistic regression was used to identify factors associated with neuropathy-related DR/PD.Results Among 121 participants, 66 (54.5%) received taxane-as-prescribed, 46 (38.0%) had neuropathy-related DR/PD, and 9 (7.4%) had DR/PD for other reasons. Factors associated with neuropathy-related DR/PD were receipt of paclitaxel (Odds Ratio [OR]=75.05, 95% Confidence Interval [CI] 2.56-2197.96]), lower pre-treatment pain catastrophizing (OR=0.72, 95% CI: 0.54 – 0.95), and higher post-treatment neuropathic pain (OR=10.77, 95% CI: 1.99 – 58.15) and sensitivity to cold pain in the hand (OR=1.64, 95% CI: 1.05 – 2.56).Conclusion CIPN-related DR/PD is associated with paclitaxel treatment and post-treatment neuropathic pain and cold pain sensitivity in the hands. CIPN communication to healthcare providers may be influenced by pain catastrophizing, suggesting symptom appraisal may be an important factor in communication. Findings could contribute to clinical practice recommendations to facilitate treatment decision-making.Lay summary We studied pre- and post-treatment factors associated with reduced taxane dose or early cessation due to chemotherapy-induced peripheral neuropathy in women undergoing chemotherapy for early-stage breast cancer. Reduced taxane dose or early cessation is associated with paclitaxel treatment, and high post-treatment neuropathic pain and sensitivity to cold pain stimuli in the hands. Communication of these experiences to healthcare providers may be influenced by pre-treatment thoughts and feelings about symptoms.Precis for use in the Table of Contents two concise sentences that state the significant conclusion(s) or message of the manuscript; Chemotherapy-induced peripheral neuropathy-related reduced taxane dose or premature discontinuation is associated with paclitaxel treatment and high post-treatment neuropathic pain and cold pain sensitivity in the upper limbs. Reporting of these experiences may be influenced by pre-treatment symptom appraisal and communication style.Competing Interest StatementRobert H. Dworkin, PhD, has received in the past 5 years research grants and contracts from the US Food and Drug Administration and the US National Institutes of Health, and compensation for serving on advisory boards or consulting on clinical trial methods from Abide, Acadia, Adynxx, Analgesic Solutions, Aptinyx, Aquinox, Asahi Kasei, Astellas, AstraZeneca, Biogen, Biohaven, Boston Scientific, Braeburn, Cardialen, Celgene, Centrexion, Chromocell, Clexio, Collegium, Concert, Confo, Decibel, Dong-A, Editas, Eli Lilly, Ethismos (equity), Eupraxia, Exicure, Glenmark, Gloriana, Grace, Hope, Immune, Lotus, Mainstay, Merck, MindMed (equity), Neumentum, Neurana, NeuroBo, Novaremed, Novartis, Olatec, OliPass, Pfizer, Phosphagenics, Quark, Reckitt Benckiser, Regenacy (also equity), Relmada, Sangamo, Sanifit, Scilex, Semnur, SIMR Bio, SK Life Sciences, Sollis, SPRIM, Teva, Theranexus, Trevena, Vertex, and Vizuri. Jennifer Gewandter, in the past 36 months, has received grant funding from the NIH and FDA. She has received consulting income from Abalone Bio, Algo Therapeutix, Asahi Kasei Pharma, GW Pharma, Disarm Therapeutics, Magnolia Neurosciences, Mitobridge, Orthogonal Neurosciences, Science Branding Communications, and SK Life Science. The remaining co-authors report no conflicts of interest related to this work. Funding StatementThis work was supported by a Canadian Pain Society/Pfizer Early Career Investigator Pain Research Grant, the Fonds de recherche du Quebe- Sante, and the Fondation J.-Louis Levesque. LRG is supported by a Fonds de recherche du Quebec-Sante Research Scholars Junior 1 award in partnership with the Quebec Breast Cancer Foundation and the Fondation J.-Louis Levesque. These funding sources had no involvement in the study design, the collection, analysis, and interpretation of the data, the writing of the report, and the decision to submit the article for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval was received from the Research Ethics Committee of the CHU de Quebec-Universite Laval, Quebec City, Quebec, Canada.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon reasonable request